Skip to main content

Christopher Ryan Kelsey

Professor of Radiation Oncology
Radiation Oncology
Radiation Oncology, Box 3085, Durham, NC 27710
30 Duke Medicine Circle, Room 05125A, Durham, NC 27710

Overview


I specialize in the treatment of hematologic and thoracic malignancies. I have a special research interest in optimizing radiation therapy in lymphomas and leukemias, particularly consolidation radiation therapy in diffuse large B-cell lymphoma and total body irradiation in the setting of allogeneic stem cell transplantation. Other academic interests include cardiac toxicity after radiation therapy for lung cancer and optimizing stereotactic body radiation therapy for stage I non-small cell lung cancer.

Current Appointments & Affiliations


Professor of Radiation Oncology · 2020 - Present Radiation Oncology, Clinical Science Departments
Member of the Duke Cancer Institute · 2017 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal Article J Natl Compr Canc Netw · October 2025 The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficac ... Full text Link to item Cite

Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma.

Journal Article Int J Radiat Oncol Biol Phys · August 1, 2025 PURPOSE: Consolidation radiation therapy (RT) is often recommended in diffuse large B-cell lymphoma. The current recommended dose of 30 Gy was established in the pre-rituximab and PET-CT era. We hypothesized that following a complete response to modern sys ... Full text Link to item Cite

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

Journal Article J Am Acad Dermatol · August 2025 INTRODUCTION: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease. SS ... Full text Link to item Cite
View All Publications

Recent Grants


Knowledge-based Tutoring for Knowledge-based Radiation Therapy

ResearchCo Investigator · Awarded by Varian Medical Systems, Inc. · 2020 - 2022

Developing knowledge models to enable rapid learning in radiation therapy

ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020

View All Grants

Education, Training & Certifications


University of Colorado, Denver · 2002 M.D.
Brigham Young University · 1998 B.S.